What were the initial Lipitor clinical trial results?
Lipitor (atorvastatin), developed by Pfizer, showed strong cholesterol-lowering effects in its first major trials in the early 1990s. The initial Phase III trial, the CURVES study (1997 publication), compared atorvastatin to other statins like simvastatin and pravastatin in 819 patients with hypercholesterolemia. Atorvastatin 10-80 mg doses reduced LDL cholesterol by 35-46% over 18 weeks, outperforming comparators (e.g., 35% reduction vs. simvastatin's 28% at equivalent doses). Total cholesterol dropped 25-37%, and triglycerides fell 20-32%, with good tolerability—discontinuation rates under 2% due to side effects like mild GI upset.[1][2]
How did these results lead to FDA approval?
These data supported FDA approval in December 1996 for primary hypercholesterolemia and mixed dyslipidemia at 10-80 mg doses. Early marketing emphasized superior potency, allowing lower doses for equivalent efficacy, which drove rapid adoption. By 1997, sales hit $1 billion, making it the top-selling drug faster than any before.[1][3]
What happened in the first outcomes trial for heart events?
The landmark ASCOT-LLA trial (2003) tested Lipitor's event reduction in 10,305 hypertensive patients with average cholesterol. Atorvastatin 10 mg cut non-fatal MI and fatal CHD by 36% (p=0.0003) vs. placebo over 3.3 years, halting the trial early. LDL fell 35%, with benefits emerging after 1 year. No overall mortality benefit, but stroke risk dropped 27%.[2][4]
Why did early results spark safety concerns?
Initial trials reported low adverse events (e.g., 1-3% myalgia), but post-approval surveillance flagged rare rhabdomyolysis (1/10,000 patient-years) and liver enzyme elevations (0.5-2%). No excess cancer or diabetes signals emerged in early data, though long-term use raised later debates.[1][5]
When did Lipitor's patent expire and generics arrive?
U.S. patent expired November 30, 2011. Ranbaxy launched first authorized generic days later, capturing 80% market share within months, dropping prices 80%. Pfizer earned $125 billion total sales.[3][6]
Sources:
[1] NEJM: CURVES Study (1997)
[2] Lancet: ASCOT-LLA (2003)
[3] DrugPatentWatch.com: Lipitor Patents & Generics
[4] NEJM: ASCOT-LLA Follow-up
[5] FDA: Lipitor Safety Data
[6] FDA: Generic Approval (2011)